Media Articles Related to Aerobid (Flunisolide Inhalation)
Researchers find potential target for drug to treat allergic asthma
Source: Health News from Medical News Today [2014.03.07]
An enzyme that helps maintain immune system function by "throwing away" a specific protein has a vital role in controlling symptoms of allergic asthma, new research in mice suggests.The finding suggests that this enzyme, called Cbl-b, could be a target for drugs used to treat allergic asthma and other autoimmune disorders.This new study, led by Ohio State University researchers, is the first to link Cbl-b to allergic asthma in an animal model.
Biologic May Tame Severe Asthma
Source: MedPage Today Allergy & Immunology [2014.03.05]
SAN DIEGO (MedPage Today) -- Lebrikizumab, a novel monoclonal antibody against the inflammatory cytokine IL-13, might have reduced exacerbations in severe asthma in a randomized trial, although manufacturing problems undermined any conclusions.
The Effect of Asthma on Fertility
Source: Medscape Allergy & Clinical Immunology Headlines [2014.03.04]
What effect might asthma have on a woman's chances of conceiving?
Medscape Allergy & Immunology
Desensitization to several food allergies aided by asthma drug
Source: Allergy News From Medical News Today [2014.03.04]
An asthma drug accelerates the process of desensitizing patients with food allergies to several foods at the same time, a new study by researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford shows.
New Phase III data demonstrate tiotropium Respimat® improves lung function versus placebo and is well tolerated in asthma patients
Source: Respiratory / Asthma News From Medical News Today [2014.03.04]
Boehringer Ingelheim has announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® Soft Mist™ Inhaler improved lung function and was well tolerated in patients with varying degrees of asthma severity.1 These data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2014 annual meeting in San Diego.
Published Studies Related to Aerobid (Flunisolide Inhalation)
Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial. [2011.10]
BACKGROUND: Inhaled corticosteroids (ICS) are the preferred long-term therapy for subjects with persistent asthma. However, concerns remain about potential effects of long-term ICS use on growth in children. OBJECTIVE: To determine the effect of 1 year of inhalation therapy with flunisolide hydrofluoroalkane (HFA) on growth velocity and bone maturation in children with mild persistent asthma... CONCLUSIONS: In this study, flunisolide HFA did not suppress growth or bone maturation at the highest approved dose for children with persistent asthma. Copyright (c) 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Intranasal flunisolide treatment in patients with non-allergic rhinitis. [2011.04]
Non-allergic rhinitis (NAR) is a heterogeneous disease, characterized by nasal hyperreactivity and inflammation...
High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children. [2009.04]
The role of inhaled corticosteroids in asthma exacerbation is debated. We compared high doses of nebulized budesonide versus high doses of nebulized flunisolide, in association with a short-acting beta-2-agonist, in the treatment of moderate asthma exacerbation in preschool children... High doses of inhaled flunisolide and budesonide are both effective in the management of moderate asthma exacerbations in pre-school-age children, but the flunisolide therapeutic effect was faster than budesonide.
Intranasal flunisolide treatment in children with adenoidal hypertrophy. [2007.10]
Adenoidal hypertrophy (AH) represents one of the most frequent indications for surgery in children and it has been proposed that treatment with intranasal corticosteroids can decrease the size of AH.In conclusion, this preliminary study demonstrates that an 8-week treatment with intranasal flunisolide is significantly associated with reduction of AH, thus preventing the recurrence to adenoidectomy, and is safe.
Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats. [2006.01]
Feline bronchial disease is commonly treated with oral glucocorticoids (OGC), which might be contraindicated in cats with certain infectious, endocrine, renal, or cardiac diseases...
Clinical Trials Related to Aerobid (Flunisolide Inhalation)
Mentored Patient-Oriented Research Career Development Award [Recruiting]
Asthmatics have inflammation in the large airways (tubes through which air travels in and
out of the lungs). The large airways are located in the central lung. New research shows
that asthmatics also have inflammation in the small airways. The small airways are located
in the peripheral lung (the parts of the lung away from the central lung).
Until now, most of the inhaled medications available have been made up of big particles that
never reach the peripheral lung. The purpose of this study is to try to measure the level of
inflammation in the peripheral lung in asthmatics and see if this inflammation can be
decreased with different types of inhaled corticosteroids. The investigators will check
airway inflammation before and after use of an inhaled corticosteroid that has a large
particle size and should only reach the large airways (Flunisolide-CFC), and before and
after use of an inhaled, small particle corticosteroid that should reach both the large and
small airways (Flunisolide-HFA).
Subjects will make 6 study visits over two phases of the study. In the first phase, the
investigators will collect baseline information about subjects while they are using placebo
(inactive substance). In the second phase, subjects will take either the large or small
Visits will involve questionnaires and various tests measuring lung function (such as
spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be
measured as an indication of inflammation. Subjects will also measure and make note of lung
function at home twice daily using a peak expiratory flow meter. Two of the visits will
involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue
samples without surgery. Another two of the visits will involve the use of high resolution
computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the
Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) [Completed]
The objective of this cross-over study is to validate the Preference Module of the EARNS-Q in
adult subjects (>=18 years of age) with Seasonal Allergic Rhinitis (SAR) taking
beclomethasone dipropionate and beclomethasone dipropionate and flunisolide.